Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
RAS pathway biomarkers for breast cancer prognosis.

Clinical laboratory international

Siewertsz van Reesema LL, Lee MP, Zheleva V, Winston JS, O'Connor CF, Perry RR, Hoefer RA, Tang AH.
PMID: 28579913
Clin Lab Int. 2016 Nov;40:18-23.

Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer...

Cite
Siewertsz van Reesema LL, Lee MP, Zheleva V, et al. RAS pathway biomarkers for breast cancer prognosis. Clin Lab Int. 2016;40:18-23
Siewertsz van Reesema, L. L., Lee, M. P., Zheleva, V., Winston, J. S., O'Connor, C. F., Perry, R. R., Hoefer, R. A., & Tang, A. H. (2016). RAS pathway biomarkers for breast cancer prognosis. Clinical laboratory international, 4018-23.
Siewertsz van Reesema, Lauren L, et al. "RAS pathway biomarkers for breast cancer prognosis." Clinical laboratory international vol. 40 (2016): 18-23.
Siewertsz van Reesema LL, Lee MP, Zheleva V, Winston JS, O'Connor CF, Perry RR, Hoefer RA, Tang AH. RAS pathway biomarkers for breast cancer prognosis. Clin Lab Int. 2016 Nov;40:18-23. PMID: 28579913; PMCID: PMC5455995.
Copy Download .nbib Format: NLM
A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.

Cancers

Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH.
PMID: 29757973
Cancers (Basel). 2018 May 14;10(5). doi: 10.3390/cancers10050142.

Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely "undruggable"....

Cite
Van Sciver RE, Lee MP, Lee CD, et al. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel). 2018;10(5)doi: 10.3390/cancers10050142.
Van Sciver, R. E., Lee, M. P., Lee, C. D., Lafever, A. C., Svyatova, E., Kanda, K., Colliver, A. L., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Zheleva, V., Bwayi, M. N., Bian, M., Schmidt, R. L., Matrisian, L. M., Petersen, G. M., & Tang, A. H. (2018). A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers, 10(5), . https://doi.org/10.3390/cancers10050142
Van Sciver, Robert E, et al. "A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology." Cancers vol. 10,5 (2018). doi: https://doi.org/10.3390/cancers10050142
Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel). 2018 May 14;10(5). doi: 10.3390/cancers10050142. PMID: 29757973; PMCID: PMC5977115.
Copy Download .nbib Format: NLM
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.

Cancers

Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH.
PMID: 32846967
Cancers (Basel). 2020 Aug 24;12(9). doi: 10.3390/cancers12092392.

Triple-negative breast cancer (TNBC), characterized by the absence or low expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), is the most aggressive subtype of breast cancer. TNBC accounts for about 15% of...

Cite
Gupta GK, Collier AL, Lee D, et al. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel). 2020;12(9)doi: 10.3390/cancers12092392.
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., Samli, B., Jansen, R. J., Petricoin, E. F., Goetz, M. P., Bear, H. D., & Tang, A. H. (2020). Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers, 12(9), . https://doi.org/10.3390/cancers12092392
Gupta, Gagan K, et al. "Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies." Cancers vol. 12,9 (2020). doi: https://doi.org/10.3390/cancers12092392
Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel). 2020 Aug 24;12(9). doi: 10.3390/cancers12092392. PMID: 32846967; PMCID: PMC7565566.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries